News

Following FDA review, Lexicon intends to initiate a phase I clinical trial of LX1031 to assess the compound's safety, tolerability and pharmacokinetics. In preclinical studies, LX1031 has demonstrated

This phase IIa trial is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PRX-03140 administered orally once-daily for 14 days in patients with mild Alzheimer's disease

Patients treated with Lunesta demonstrated statistically significant improvement in measures of onset of sleep time spent awake and total sleep time. Secondary measures of sleep quality, depth of

The application is designed to permit initial clinical testing of Tripep's proprietary DNA vaccine, ChronVac-C, administered using Inovio's MedPulser DNA Delivery System. This combination is designed to activate

Chronic lymphocytic leukemia is the most common hematologic malignancy in the western hemisphere and remains incurable, said the researchers. While several phase II studies have demonstrated improved clinical

The new labeling includes revised “Precautions” and “Clinical Pharmacology: Pharmacokinetics” sections. Skelaxin is indicated as an adjunct to rest, physical therapy, and other measures for the relief of

A separate but related evaluation license agreement has been entered into between University of California, San Diego (UCSD) Office of Technology Transfer and Intellectual Property Services and Medarex

According to Nastech, P&G discussed performing an additional clinical study not included in the original agreement. Subsequently a contract amendment was executed and the $15 million in payments

As previously reported, Abbott commenced a tender offer for all of the outstanding shares of Kos common stock for $78.00 per share or $3.7 billion in cash. The